The Top 5 Biosimilars Articles for the Week of August 14

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars^®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 14.

Number 5: Biocon has withdrawn its filings for 2 biosimilars in Europe ahead of a re-inspection of its Bangalore manufacturing facility. The move sparked new questions as to whether the company’s trastuzumab will be cleared by the FDA next month.

Number 4: Dr Marcus Snow, of the University of Nebraska Medical Center, joined The Center for Biosimilars^® to discuss the use of biosimilar treatments in children.

Number 3: With drug price reform efforts apparently stalled at the federal level, states are leading the fight against rising drug costs.

Number 2: A recent budget impact analysis shows that discounts for biosimilar infliximab may need to be deeper than previously believed in order to encourage uptake.

And Number 1: Rebates provided to PBMs by reference product sponsors may pose a threat to biosimilar uptake, and could force patients to pay high out-of-pocket costs.

Finally, last week, our newsletter asked you to share your thoughts on switching studies, and whether such studies should use a US-licensed reference product, an EU-licensed product, or a product approved by any global healthcare agency. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.

To read these articles and more, visit centerforbiosimilars.com.